Artivila Therapeutics

Artivila Therapeutics (Ke Hui Zhi Yao) develops innovative therapeutics using a dual AI+HI (Artificial Intelligence + Human Intelligence) engine-driven drug discovery platform, focusing on oncology, autoimmune diseases, and neurodegenerative diseases. The company integrates computational chemistry, artificial intelligence, synthetic chemistry, analytical chemistry, life sciences, and pharmacology across multiple disciplines to significantly reduce R&D costs, shorten development cycles, improve success rates, and unlock challenging research areas. The platform leverages advanced AI technology combined with the successful drug development experience of top scientists from multinational pharmaceutical companies to design and develop first-in-class innovative drugs with broad commercial potential. Artivila aims to discover new drug targets and address unmet medical needs by designing therapeutics that can change patient outcomes. Founded in 2018 and headquartered in Shenzhen, China, the company has raised approximately $22.8 million at the seed stage.